Development of an Excipient-Free Peptide Dry Powder Inhalation for the Treatment of Pulmonary Fibrosis

A Simple Practice Guide for Dose Conversion between Animals and Human

Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174 · see citing works

Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy

Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,788 · see citing works

Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications

Labiris, N. R., & DOLOVICH, M. B. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01892.x · Cited by 1,259 · see citing works

Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157 · see citing works

Stability of Protein Pharmaceuticals: An Update

Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-009-0045-6 · Cited by 1,103 · see citing works

Idiopathic Pulmonary Fibrosis

Gross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 970 · see citing works

The Epidemiology of Interstitial Lung Diseases

Coultas, D., Zumwalt, R., Black, W. C., & Sobonya, R. E. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.4.7921471 · Cited by 948 · see citing works

Formulation strategy and use of excipients in pulmonary drug delivery

Pilcer, G., & Amighi, K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.017 · Cited by 791 · see citing works

Inhaled nanoparticles—A current review

Yang, W. P., Peters, J. I., & Williams, R. O. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.02.011 · Cited by 670 · see citing works

Caveolin-1 Regulates Transforming Growth Factor (TGF)-β/SMAD Signaling through an Interaction with the TGF-β Type I Receptor

Razani, B., Zhang, X. L., Bitzer, M., von Gersdorff, G., Böttinger, E. P., & Lisanti, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008340200 · Cited by 640 · see citing works

Antifibrotic activities of pirfenidone in animal models

Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454 · see citing works

Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis

Wang, X. M., Zhang, Y., Kim, H. P., Zhou, Z., Feghali-Bostwick, C. A., Liu, F., Ifedigbo, E., Xu, X., Oury, T. D., Kaminski, N., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061536 · Cited by 397 · see citing works

Elements of materials science and engineering

Vlack, V., & Lawrence, H. (1959) · Cited by 377 · see citing works

The Bleomycin Model of Pulmonary Fibrosis

Liu, T., Santos, F. G. D. L., & Phan, S. H. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7113-8_2 · Cited by 360 · see citing works

Pharmacologic Differentiation of Inflammation and Fibrosis in the Rat Bleomycin Model

Chaudhary, N. I., Schnapp, A., & Park, J. E. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200505-717oc · Cited by 359 · see citing works

Protein Inhalation Powders: Spray Drying vs Spray Freeze Drying

Maa, Y., Nguyen, P., Sweeney, T. D., Shire, S. J., & Hsu, C. C. (1999) · Pharmaceutical Research · doi:10.1023/a:1018828425184 · Cited by 356 · see citing works

Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib

Karimi-Shah, B. A., & Chowdhury, B. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500526 · Cited by 316 · see citing works

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial

Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1301oc · Cited by 305 · see citing works

Particle engineering techniques for inhaled biopharmaceuticals

Shoyele, S., & Cawthorne, S. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.010 · Cited by 304 · see citing works

Cation-π Interactions Involving Aromatic Amino Acids

Dougherty, D. A. (2007) · Journal of Nutrition · doi:10.1093/jn/137.6.1504s · Cited by 303 · see citing works

Dry powder inhalers (DPIs)—A review of device reliability and innovation

Islam, N., & Gladki, E. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.044 · Cited by 300 · see citing works

Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance

Bosquillon, C., Lombry, C., Véronique Préat, A., & Rita Vanbever, A. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00362-x · Cited by 296 · see citing works

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U. (2017) · European Respiratory Review · doi:10.1183/16000617.0057-2017 · Cited by 295 · see citing works

Collagen polymorphism in idiopathic chronic pulmonary fibrosis.

Seyer, J. M., Hutcheson, E. T., & Kang, A. H. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108420 · Cited by 266 · see citing works

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat

Maher, T. M., & Strek, M. E. (2019) · Respiratory Research · doi:10.1186/s12931-019-1161-4 · Cited by 266 · see citing works

Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions

Galli, J. A., Pandya, A., Vega‐Olivo, M., Dass, C. A., Zhao, H., & Criner, G. J. (2017) · Respirology · doi:10.1111/resp.13024 · Cited by 258 · see citing works

Use of Solid Corrugated Particles to Enhance Powder Aerosol Performance

Chew, N. Y. K., & Chan, H. (2001) · Pharmaceutical Research · doi:10.1023/a:1013082531394 · Cited by 252 · see citing works

Process-Induced Crystallinity Changes in Albuterol Sulfate and Its Effect on Powder Physical Stability

Ward, G. H., & Schultz, R. K. (1995) · Pharmaceutical Research · doi:10.1023/a:1016232230638 · Cited by 230 · see citing works

Bleomycin Induces Molecular Changes Directly Relevant to Idiopathic Pulmonary Fibrosis: A Model for “Active” Disease

Peng, R., Sridhar, S., Tyagi, G., Phillips, J. E., Garrido, R., Harris, P., Burns, L., Renteria, L., Woods, J., Chen, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059348 · Cited by 226 · see citing works

Collagen polymorphism in the lungAn immunochemical study of pulmonary fibrosis

Madri, J. A., & Furthmayr, H. (1980) · Human Pathology · doi:10.1016/s0046-8177(80)80031-1 · Cited by 219 · see citing works

Unlocking the quiet zone: the small airway asthma phenotype

Lipworth, B. J., Manoharan, A., & Anderson, W. J. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70103-1 · Cited by 215 · see citing works

Supercritical Fluid Technology for Drug Product Development

York, Y. (2004) · CRC Press eBooks · doi:10.1201/9780203021378 · Cited by 202 · see citing works

The Influence of Fine Excipient Particles on the Performance of Carrier-Based Dry Powder Inhalation Formulations

Jones, M. D., & Price, R. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9012-7 · Cited by 194 · see citing works

The Effect of Formulation Excipients on Protein Stability and Aerosol Performance of Spray-Dried Powders of a Recombinant Humanized Anti-IgE Monoclonal Antibody1

Andya, J. D., Maa, Y., Costantino, H. R., Nguyen, P., Dasovich, N., Sweeney, T. D., Hsu, C. C., & Shire, S. J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018805232453 · Cited by 190 · see citing works

Drug Treatment of Idiopathic Pulmonary Fibrosis

Canestaro, W. J., Forrester, S. H., Raghu, G., Ho, L. A., & Devine, B. E. (2016) · CHEST Journal · doi:10.1016/j.chest.2015.11.013 · Cited by 186 · see citing works

Pharmacokinetics of inhaled drugs

Lipworth, B. J. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.00493.x · Cited by 181 · see citing works

Dry powder formulations for pulmonary delivery

Malcolmson, R., & Embleton, J. K. (1998) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(98)00099-6 · Cited by 177 · see citing works

Influence of physical properties of carrier on the performance of dry powder inhalers

Peng, T., Lin, S., Niu, B., Wang, X., Huang, Y., Zhang, X., Li, G., Pan, X., & Wu, C. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.03.011 · Cited by 177 · see citing works

Review of dry powder inhalers

Prime, D. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00510-3 · Cited by 170 · see citing works

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis

Hughes, G., Toellner, H., Morris, H. G., Leonard, C. T., & Chaudhuri, N. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5090078 · Cited by 167 · see citing works

The inhalers of the future? A review of dry powder devices on the market today

Smith, I., & Parry‐Billings, M. (2003) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/s1094-5539(02)00147-5 · Cited by 162 · see citing works

The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro

Zeng, X. M., Martin, G. P., Tee, S. K., & Marriott, C. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00300-7 · Cited by 158 · see citing works

Effects of Dry Grinding on the Structural Changes of Kaolinite Powders

Sánchez-Soto, P. J., de Haro, M. C. J., Pérez-Maqueda, L. A., Varona, I., & Pérez-Rodrı́guez, J. L. (2000) · Journal of the American Ceramic Society · doi:10.1111/j.1151-2916.2000.tb01444.x · Cited by 149 · see citing works

Influence of surface chemistry and topography of particles on their immersion into the lung's surface-lining layer

Geiser, M., Schürch, S., & Gehr, P. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00514.2002 · Cited by 148 · see citing works

Ion Transport by Pulmonary Epithelia

Hollenhorst, M. I., Richter, K., & Fronius, M. (2011) · BioMed Research International · doi:10.1155/2011/174306 · Cited by 145 · see citing works

Spray Dried Powders and Powder Blends of Recombinant Human Deoxyribonuclease (rhDNase) for Aerosol Delivery

Chan, H., Clark, A., Gonda, I., Mumenthaler, M., & Hsu, C. C. (1997) · Pharmaceutical Research · doi:10.1023/a:1012035113276 · Cited by 141 · see citing works

Pulmonary Fibrosis Deaths in the United States, 1979-1991. An Analysis of Multiple-Cause Mortality Data

Mannino, D. M., Etzel, R. A., & Parrish, R. G. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.5.8630600 · Cited by 140 · see citing works

Preparation of peptide and protein powders for inhalation

Johnson, K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00506-1 · Cited by 139 · see citing works

A review of the technical aspects of drug nebulization.

Brun, P. P. H. L., de Boer, A. H., Frijlink, H. W., & Heijerman, H. G. M. (2000) · Pharmacy World & Science · doi:10.1023/a:1008786600530 · Cited by 134 · see citing works

Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations

Donovan, M. J., & Smyth, H. D. C. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.08.045 · Cited by 120 · see citing works

The Failure of Exubera: Are We Beating a Dead Horse?

Heinemann, L. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200325 · Cited by 119 · see citing works

The impact of electrostatic charge in pharmaceutical powders with specific focus on inhalation-powders

Karner, S., & Urbanetz, N. A. (2011) · Journal of Aerosol Science · doi:10.1016/j.jaerosci.2011.02.010 · Cited by 118 · see citing works

Devices for Dry Powder Drug Delivery to the Lung

Berkenfeld, K., Lamprecht, A., & McConville, J. T. (2015) · AAPS PharmSciTech · doi:10.1208/s12249-015-0317-x · Cited by 117 · see citing works

Role of caveolin-1 in fibrotic diseases

Gvaramia, D., Blaauboer, M. E., Hanemaaijer, R., & Everts, V. E. (2013) · Matrix Biology · doi:10.1016/j.matbio.2013.03.005 · Cited by 109 · see citing works

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

Richeldi, L., Kreuter, M., Selman, M., Crestani, B., Kirsten, A., Wuyts, W. A., Xu, Z., Bernois, K., Stowasser, S., Quaresma, M., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209701 · Cited by 107 · see citing works

A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics

Chan, J. G. Y., Chan, H., Prestidge, C. A., Denman, J. A., Young, P. M., & Traini, D. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.08.007 · Cited by 100 · see citing works

Concentration, biosynthesis and degradation of collagen in idiopathic pulmonary fibrosis.

Selman, M., Montaño, M., Ramos, C., & Chapela, R. (1986) · Thorax · doi:10.1136/thx.41.5.355 · Cited by 96 · see citing works

Cyclodextrins as Drug Carriers in Pharmaceutical Technology: The State of the Art

Conceição, J., Adeoye, O., Cabral-Marques, H. M., & Lobo, J. M. S. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612824666171218125431 · Cited by 96 · see citing works

Characterisation of the surface energetics of milled dl-propranolol hydrochloride using inverse gas chromatography and molecular modelling

York, P., Ticehurst, M. D., Osborn, J. C., Roberts, R. J., & Rowe, R. C. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00247-6 · Cited by 95 · see citing works

Formulation and Characterization of Lipid-Coated Tobramycin Particles for Dry Powder Inhalation

Pilcer, G., Sebti, T., & Amighi, K. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9789-4 · Cited by 94 · see citing works

Regional particle size dependent deposition of inhaled aerosols in rats and mice

Kuehl, P. J., Anderson, T. L., Candelaria, G. A., Gershman, B., Harlin, K., Hesterman, J. Y., Holmes, T. D., Hoppin, J. W., Lackas, C., Norenberg, J. P., et al. (2011) · Inhalation Toxicology · doi:10.3109/08958378.2011.632787 · Cited by 91 · see citing works

Technique training does not improve the ability of most patients to use pressurised metered-dose inhalers (pMDIs)

Hardwell, A., Barber, V., Hargadon, T., McKnight, E., Holmes, J., & Levy, M. L. (2011) · Primary Care Respiratory Journal · doi:10.4104/pcrj.2010.00088 · Cited by 89 · see citing works

Caveolin-1–derived peptide limits development of pulmonary fibrosis

Marudamuthu, A. S., Bhandary, Y. P., Fan, L., Radhakrishnan, V., MacKenzie, B., Maier, E., Shetty, S. K., Nagaraja, M. R., Gopu, V., Tiwari, N., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat2848 · Cited by 86 · see citing works

Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing

Irngartinger, M., Camuglia, V., Damm, M., Goede, J., & Frijlink, H. W. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.016 · Cited by 80 · see citing works

Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system

Bhandary, Y. P., Shetty, S. K., Marudamuthu, A. S., Gyetko, M. R., Idell, S., Gharaee‐Kermani, M., Shetty, R. R., STARCHER, B. C., & Shetty, S. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00099.2011 · Cited by 79 · see citing works

Formation of Stable Submicron Protein Particles by Thin Film Freezing

Engstrom, J. D., Lai, E. S., Ludher, B. S., Chen, B., Milner, T. E., Williams, R. O., Kitto, G. B., & Johnston, K. P. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9540-4 · Cited by 79 · see citing works

Does size really matter?: Relationship of particle size to lung deposition and exhaled fraction

Jabbal, S., Poli, G., & Lipworth, B. J. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.11.036 · Cited by 76 · see citing works

The Influence of Mechanical Processing of Dry Powder Inhaler Carriers on Drug Aerosolization Performance

Young, P. M., Chan, H., Chiou, H., Edge, S., Tee, T. H. S., & Traini, D. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20933 · Cited by 72 · see citing works

Recent advancements in mechanical reduction methods: particulate systems

Leleux, J. A., & Williams, R. O. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2013.828217 · Cited by 67 · see citing works

Particle size and composition effects in x-ray fluorescence analysis of pollution samples

Criss, J. W. (1976) · Analytical Chemistry · doi:10.1021/ac60365a003 · Cited by 66 · see citing works

Symposium Summary

Tepper, J. S., Kuehl, P. J., Cracknell, S., Nikula, K. J., Pei, L., & Blanchard, J. D. (2016) · International Journal of Toxicology · doi:10.1177/1091581815624080 · Cited by 63 · see citing works

Inhaled versus nebulised tobramycin: A real world comparison in adult cystic fibrosis (CF)

Harrison, M. J., McCarthy, M. M., Fleming, C., Hickey, C., Shortt, C., Eustace, J., Murphy, D. M., & Plant, B. J. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.04.004 · Cited by 59 · see citing works

Is There a Potential Therapeutic Role for Caveolin-1 in Fibrosis?

Shihata, W., Putra, M. R. A., & Chin-Dusting, J. P. F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00567 · Cited by 52 · see citing works

Excipient-Free Pulmonary Delivery and Macrophage Targeting of Clofazimine via Air Jet Micronization

Brunaugh, A. D., Jan, S. U., Ferrati, S., & Smyth, H. D. C. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00690 · Cited by 51 · see citing works

The p53–Mdm2 association in epithelial cells in idiopathic pulmonary fibrosis and non-specific interstitial pneumonia

Nakashima, N., Kuwano, K., Maeyama, T., Hagimoto, N., Yoshimi, M., Hamada, N., Yamada, M., & Nakanishi, Y. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.022632 · Cited by 50 · see citing works

SMAD-Independent Down-Regulation of Caveolin-1 by TGF-β: Effects on Proliferation and Survival of Myofibroblasts

Sanders, Y. Y., Cui, Z., Le Saux, C. J., Horowitz, J. C., Rangarajan, S., Kurundkar, A., Antony, V. B., & Thannickal, V. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116995 · Cited by 49 · see citing works

Aerosolization behavior of carrier-free l-leucine coated salbutamol sulphate powders

Raula, J., Lähde, A., & Kauppinen, E. I. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.08.017 · Cited by 45 · see citing works

Effect of crystal, grain, and particle size on X-ray power diffracted from powders

Wilchinsky, Z. W. (1951) · Acta Crystallographica · doi:10.1107/s0365110x51000015 · Cited by 42 · see citing works

Expression of Caveolin-1 reduces cellular responses to TGF-β1 through down-regulating the expression of TGF-β type II receptor gene in NIH3T3 fibroblast cells

Lee, E. K., Lee, Y. S., Han, I.-O., & Park, S. H. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.121 · Cited by 38 · see citing works

Epigenetic Regulation of Caveolin-1 Gene Expression in Lung Fibroblasts

Sanders, Y. Y., Liu, H., Scruggs, A. M., Duncan, S. R., Huang, S. K., & Thannickal, V. J. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0034oc · Cited by 38 · see citing works

Evaluation of Granulated Lactose as a Carrier for DPI Formulations 1: Effect of Granule Size

Du, P., Du, J., & Smyth, H. D. C. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0166-z · Cited by 38 · see citing works

Mixing Time Effects on the Dispersion Performance of Adhesive Mixtures for Inhalation

Grasmeijer, F., Hagedoorn, P., Frijlink, H. W., & de Boer, H. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069263 · Cited by 37 · see citing works

Evaluation of the potential of air jet milling of solid protein-poly(acrylate) complexes for microparticle preparation

Schlocker, W., GSCHLIESER, S., & Bernkop‐Schnürch, A. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.09.001 · Cited by 33 · see citing works

Role of p53–fibrinolytic system cross-talk in the regulation of quartz-induced lung injury

Bhandary, Y. P., Shetty, S. K., Marudamuthu, A. S., Fu, J., Pinson, B., Levin, J. L., & Shetty, S. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.01.007 · Cited by 30 · see citing works

Inhaled Insulin is Better Absorbed When Administered as a Dry Powder Compared to Solution in the Presence or Absence of Alkylglycosides

Hussain, A., Majumder, Q. H., & Ahsan, F. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8926-9 · Cited by 30 · see citing works

Inhaled Alpha 1-Antitrypsin: Gauging Patient Interest in a New Treatment

Monk, R., Graves, M., Williams, P. H., & Strange, C. (2013) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2012.758698 · Cited by 29 · see citing works

Hollow crystalline straws of diclofenac for high-dose and carrier-free dry powder inhaler formulations

Yazdi, A. K., & Smyth, H. D. C. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.02.030 · Cited by 27 · see citing works

Beclomethasone dipropionate dry-powder inhalation compared with conventional aerosol in chronic asthma.

Carmichael, J., Duncan, D. B., & Crompton, G. K. (1978) · BMJ · doi:10.1136/bmj.2.6138.657 · Cited by 23 · see citing works

Induction of p53 by Urokinase in Lung Epithelial Cells

Shetty, S., Gyetko, M. R., & Mazar, A. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413190200 · Cited by 21 · see citing works

Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler

Hindle, M., Peers, E. M., Parry‐Billings, M., & Chrystyn, H. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00564.x · Cited by 20 · see citing works

Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON

Crestani, B., Quaresma, M., Kaye, M. G., Stansen, W., Stowasser, S., & Kreuter, M. (2016) · European Respiratory Journal · doi:10.1183/13993003.congress-2016.oa4960 · Cited by 19 · see citing works

Usage and Usability of One Dry Powder Inhaler Compared to Other Inhalers at Therapy Start: An Open, Non-interventional Observational Study in Poland and Germany

Hantulik, P., Wittig, K., Henschel, Y., Ochse, J., Vahteristo, M., & Rytilä, P. H. (2015) · Advances in respiratory medicine · doi:10.5603/piap.2015.0059 · Cited by 18 · see citing works

New guideline for idiopathic pulmonary fibrosis

Stowasser, S., & Hallmann, C. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00765-5 · Cited by 10 · see citing works

Formulation Challenges

Hak-Kim, C. (2002) · Drugs and the pharmaceutical sciences · doi:10.1201/9780203910337.ch74 · Cited by 2 · see citing works

Pulmonary Delivery of Biological Drugs

Liang, W., Pan, H. W., Vllasaliu, D., & Lam, J. K. W. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111025 · Cited by 187 · see citing works

Novel drug delivery systems and disease models for pulmonary fibrosis

Li, R., Jia, Y., Kong, X., Nie, Y., Deng, Y., & Liu, Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.039 · Cited by 93 · see citing works

Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment

Ghumman, M., Dhamecha, D. L., Gonsalves, A., Fortier, L., Sorkhdini, P., Zhou, Y., & Menon, J. U. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.017 · Cited by 79 · see citing works

Just how prevalent are peptide therapeutic products? A critical review

Zhang, Y., Zhang, H., Ghosh, D., & Williams, R. O. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119491 · Cited by 75 · see citing works

Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics

Chang, R. Y. K., & Chan, H. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03363-2 · Cited by 64 · see citing works

Antioxidant Biodegradable Covalent Cyclodextrin Frameworks as Particulate Carriers for Inhalation Therapy against Acute Lung Injury

He, S., Wu, L., Sun, H., Wu, D., Wang, C., Ren, X., Shao, Q., York, P., Tong, J., Zhu, J., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c05220 · Cited by 58 · see citing works

Protein and peptide delivery to lungs by using advanced targeted drug delivery

Chellappan, D. K., Prasher, P., Saravanan, V., Yee, V. S. V., Wen, W. C., Wong, J. W., Wong, J. K., Wong, J. T., Wan, W. Y., Chellian, J., et al. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109706 · Cited by 48 · see citing works

Novel formulations and drug delivery systems to administer biological solids

Zhang, Y., Davis, D. A., AboulFotouh, K., Wang, J., Williams, D., Bhambhani, A., Zakrewsky, M., Maniruzzaman, M., Cui, Z., & Williams, R. O. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.011 · Cited by 47 · see citing works

Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline

Wong, S. N., Weng, J., Ip, I., Chen, R., Lakerveld, R., Telford, R., Blagden, N., Scowen, I. J., & Chow, S. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020300 · Cited by 46 · see citing works

Emerging trends in pulmonary delivery of biopharmaceuticals

Kunde, S. S., Ghosh, R., & Wairkar, S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.003 · Cited by 35 · see citing works

Engineering Inhalable Therapeutic Particles: Conventional and Emerging Approaches

Negi, A., Nimbkar, S., & Moses, J. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122706 · Cited by 29 · see citing works

Chemo-photodynamic therapy by pulmonary delivery of gefitinib nanoparticles and 5-aminolevulinic acid for treatment of primary lung cancer of rats

Zhang, T., Bao, J., Zhang, M., Ge, Y., Wei, J., Yu, L., Wang, W., Li, M., & Jin, Y. (2020) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2020.101807 · Cited by 28 · see citing works

Improvement of the pharmacokinetics and antifibrotic effects of nintedanib by intrapulmonary administration of a nintedanib–hydroxypropyl-γ-cyclodextrin inclusion complex in mice with bleomycin-induced pulmonary fibrosis

Togami, K., Ogasawara, A., Irie, S., Iwata, K., Yamaguchi, K., Tada, H., & Chono, S. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.02.009 · Cited by 18 · see citing works

Inhalable Excipient-Free Dry Powder of Tigecycline for the Treatment of Pulmonary Infections

Nair, V. V., & Smyth, H. D. C. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00395 · Cited by 16 · see citing works

Design, synthesis, and biological evaluation of indolin-2-one derivatives as novel cyclin-dependent protein kinase 8 (CDK8) inhibitors

Hsu, J., Hsu, K., Sun, C., Chou, C.-H., Lin, T. E., Sung, T.-Y., Tseng, H.-J., Yen, S., Yang, C., & Huang, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114258 · Cited by 15 · see citing works

Therapeutic Peptide Delivery: Fundamentals, Formulations, and Recent Advances

Vora, D., Dandekar, A. A., & Banga, A. K. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-04544-8_5 · Cited by 14 · see citing works

Particulate platform for pulmonary drug delivery: Recent advances of formulation and fabricating strategies

Zhang, Z., Jin, M., Yang, X., Zhu, H., Li, H., & Yang, Q. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125601 · Cited by 13 · see citing works

Nanocrystal Agglomerates of Curcumin Prepared by Electrospray Drying as an Excipient‐Free Dry Powder for Inhalation

Emami, S., Hemmati, Z., Yaqoubi, S., Hamishehkar, H., & Alvani, A. (2024) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2024/6288621 · Cited by 11 · see citing works

Advancements in nanotechnology for targeted drug delivery in idiopathic pulmonary fibrosis: a focus on solid lipid nanoparticles and nanostructured lipid carriers

Suriya Prakaash, K. K., & Narayanasamy, D. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2468811 · Cited by 10 · see citing works

Crystallizing the Role of Solid-State Form in Drug Delivery

Taylor, L. S., Braun, D. E., Tajber, L., & Steed, J. W. (2022) · Crystal Growth & Design · doi:10.1021/acs.cgd.2c00760 · Cited by 8 · see citing works

Excipients in pharmaceuticals: mechanisms of hypersensitivity and the role of global pharmacovigilance

Malkawi, R., & Altahrawi, L. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00004-8 · Cited by 7 · see citing works

LTI-03 peptide demonstrates anti-fibrotic activity in ex vivo lung slices from patients with IPF

MacKenzie, B., Mahavadi, P., Pinho Jannini-Sa, Y. A., Creyns, B., Coelho, A. L., Espindola, M., Ruppert, C., Windsor, B., Aigner, C., Hogaboam, C. M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113437 · Cited by 2 · see citing works

Crystallizing the Role of Solid-State Form in Drug Delivery

Taylor, L. S., Braun, D. E., Tajber, L., & Steed, J. W. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00562 · Cited by 2 · see citing works

Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study

Molyneaux, P. L., Hirani, N. A., Chia, C. C. K., Kulkarni, T., Zaman, T., Kaner, R. J., Coelho, A. L., Jannini-Sa, Y. A. P., Windsor, B., Kruger, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75291-3 · Cited by 1 · see citing works

Design Strategies of Dry Powders for Pulmonary Delivery of Pharmaceutical Peptides

Sato, H. (2023) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-47567-2_1 · Cited by 1 · see citing works

Lipid-Based Nanocarriers: A Frontier in Cystic Fibrosis Therapy

Singh, A. N., Maheshwari, S., Verma, A., Kumar, P., Mishra, V. M., Dwivedi, S., & Prajapati, B. G. (2025) · Biomedical Materials & Devices · doi:10.1007/s44174-025-00333-1

An overview of dry powder inhaler production methods

Aygüler, C. İ., Dağıstan, Ö. A., & Yıldız-Peköz, A. (2025) · Journal of Research in Pharmacy · doi:10.12991/jrespharm.1712419

Mechanochemical Engineering of High-Dose Inhalable Antibiotic Powders for Lower Respiratory Tract Infections

Sun, X., Bolhuis, A., Jones, M. D., Ganley, W. J., Fotaki, N., Bachiller, M. N., & Dominguez, B. C. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00936

Inhalable stealth liposomes improve peptide delivery for pulmonary fibrosis treatment

Lin, R., Li, Z., Sun, Y., Shen, J., Cao, X., Lin, Y., Fu, C. L., Zhu, Y., Wang, C., Tan, Z., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114655 · Cited by 3 · see citing works

Development of dry powder inhalation for biological drug modalities

Zhang, Y. (2020) · Texas Digital Library (University of Texas) · doi:10.26153/tsw/42240

Pulmonary delivery of silk fibroin peptides dry powder inhalers for idiopathic pulmonary fibrosis

倪金梅, Chen, M., Wu, Z., Zhang, Q., Wang, L., & Che, X. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2680984

Dry Powder Inhalers for Proteins Using Cryo-Milled Electrospun Polyvinyl Alcohol Nanofiber Mats

Ito, T., Yamazoe, E., & Tahara, K. (2022) · Molecules · doi:10.3390/molecules27165158 · Cited by 16 · see citing works

Caveolin-1–derived peptide limits development of pulmonary fibrosis

Marudamuthu, A. S., Bhandary, Y. P., Fan, L., Radhakrishnan, V., MacKenzie, B., Maier, E., Shetty, S. K., Nagaraja, M. R., Gopu, V., Tiwari, N., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat2848 · Cited by 86 · see citing works